Indication
Treatment and prophylaxis of bleeding in patients 12 years and above with haemophilia A (congenital factor VIII deficiency).
Loading your page…
Loading your page…
Hemophilia A
Marketing Authorisation Holder: Baxalta Innovations GmbH
EMA Authorisation: 08/01/2018
INN: rurioctocog alfa pegol
AI Drug & Interaction Analysis
Free account required
Ask Osler about Adynovi: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.